Increased Malat1 Expression Predicts Poor Prognosis in Primary Gastrointestinal Diffuse Large B-cell Lymphoma
Source : https://europepmc.org/article/ppr/ppr296017
Increased Malat1 Expression Predicts Poor Prognosis in Primary Gastrointestinal Diffuse Large B-cell Lymphoma
-
Mark Fesler4yrMalat1 hasn’t received much attention in lymphoma and this opens a potentially important line of future research both from a prognostic and predictive standpoint
End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33651099/
GOYA was a randomized phase 3 study comparing obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) vs standard-of-care rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma...
-
Mark Fesler4yrWhile one would assume a link between end of treatment pet cR vs other response category would predict pfs in an aggressive and curable disease , it’s always nice to Show More
-
Mark Fesler4yrThis case highlights the importance of a comprehensive flow histopath genetic and molecular workup on blood cancers as variants of even rare subtypes do exist and this becomes critical info Show More
Incorporating Novel Targeted and Immunotherapeutic Agents in Treatment of B-Cell Lymphomas - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33770460/
The introduction of novel targeted agents and immunotherapeutic modalities into the treatment of B-cell lymphomas has drastically shifted the treatment landscape. In diffuse large B-cell lymphoma, recent approvals of CAR...
-
Mark Fesler4yrWe are likely at the tip of the iceberg in regards to immunotherapy as additional car T, nk cell therapy, and bispecific immunotherapy are likely to see expansion and integration Show More
The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33781518/
CD19-targeted chimeric antigen receptor (CAR) T cells have shown excellent activity against relapsed and refractory (R/R) diffuse large B cell lymphoma (DLBCL). CAR T cell therapy is associated with early...
-
Mark Fesler4yrGiven that carTs often cancel higher risk subsets of disease, such as double hit genetics, it’s surprising that a simple clinical risk score would be predictive of outcome ....